The state of Illinois currently has 37 active clinical trials seeking participants for Hypertension research studies. These trials are conducted in various cities, including Chicago, Peoria, Springfield and Urbana.
A Study to Evaluate Cortisol Reserve in Response to Adrenocorticotropic Hormone (ACTH) Stimulation Test Following Baxdrostat Treatment Compared to Placebo in Participants With Uncontrolled Hypertension
Recruiting
The main purpose of this study is to assess the serum free cortisol response after ACTH stimulation test at baseline and at Week 8 in participants with uncontrolled hypertension.
Gender:
All
Ages:
Between 18 years and 130 years
Trial Updated:
06/19/2024
Locations: Research Site, Chicago, Illinois
Conditions: Uncontrolled Hypertension
Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension
Recruiting
The purpose of this study is to demonstrate superiority of macitentan 75 milligrams (mg) in prolonging the time to the first clinical events committee (CEC)-adjudicated morbidity or mortality (M/M) event in participants with symptomatic pulmonary arterial hypertension (PAH) compared to macitentan 10 mg.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: Advocate Christ Medical Center, Oak Lawn, Illinois
Conditions: Pulmonary Arterial Hypertension
An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH)
Recruiting
The primary purpose of the study is to evaluate the safety and tolerability of the long-term use of TPIP in participants with PAH from studies INS1009-201 (NCT04791514), INS1009-202 (NCT05147805) and other lead-in studies of TPIP in participants with PAH.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: USA006, Chicago, Illinois +1 locations
Conditions: Pulmonary Arterial Hypertension
MK-5475-013 INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of MK-5475 (an Inhaled sGC Stimulator) in Adults With PH-COPD
Recruiting
The purpose of this study is to evaluate the safety and efficacy of once daily oral inhalation dose of MK-5475 380 µg in participants 40 to 85 years (inclusive) with Pulmonary Hypertension associated with Chronic Obstructive Pulmonary Disease (PH-COPD). The primary hypothesis of the study is MK-5475, a soluble Guanylate Cyclase (sGC) stimulator is superior to placebo in increasing 6 Minute Walking Distance (6MWD) from baseline at Week 24.
Gender:
All
Ages:
Between 40 years and 85 years
Trial Updated:
06/14/2024
Locations: Alexian Brothers Medical Center-Pulmonary ( Site 0109), Elk Grove Village, Illinois
Conditions: Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
TIPS Plus Transvenous Obliteration for Gastric Varices
Recruiting
Variceal hemorrhage (VH) from gastric varices (GVs) results in significant morbidity and mortality among patients with liver cirrhosis. In cases of acute bleeding, refractory bleeding, or high risk GVs, the transjugular intrahepatic portosystemic shunt (TIPS) creation and transvenous variceal obliteration procedures have used to treat GVs. While these techniques are effective, each is associated with limitations, including non-trivial rebleeding and hepatic encephalopathy rates for TIPS and aggr... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/14/2024
Locations: University of Illinois at Chicago, Chicago, Illinois
Conditions: Cirrhosis, Liver, Hypertension, Portal, Esophageal and Gastric Varices, Bleeding Gastric, Encephalopathy
A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16)
Recruiting
This is a Phase 2, double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of sotatercept versus placebo in adults with Cpc-PH due to HFpEF. The objective of this study is to evaluate the efficacy, safety and tolerability of sotatercept versus placebo in adults with Cpc-PH due to HFpEF. Efficacy is measured by change from baseline in pulmonary vascular resistance (PVR, primary endpoint) and 6-minute walk distance (6MWD, key secondary endpoint).
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
06/14/2024
Locations: University of Illinois Hospital ( Site 1095), Chicago, Illinois
Conditions: Hypertension, Pulmonary
LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF
Recruiting
This study will evaluate the efficacy of TNX-103 (levosimendan) compared with placebo in subjects with PH-HFpEF as measured by the change in 6-Minute Walk Distance (6 MWD; Day 1 to Week 12).
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
06/14/2024
Locations: Northwestern University, Chicago, Illinois
Conditions: Pulmonary Hypertension
Virtual Diabetes Group Visits Across Health Systems
Recruiting
The purpose of this project is to evaluate the effectiveness of a virtual diabetes group visits on patients with type 2 diabetes mellitus (T2DM).
Gender:
All
Ages:
18 years and above
Trial Updated:
06/13/2024
Locations: Access Community Health Network, Chicago, Illinois +1 locations
Conditions: T2DM (Type 2 Diabetes Mellitus), Hypertension, Heart Disease Chronic, Stroke, Hyperlipidemias, Peripheral Vascular Diseases, Obesity
Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension
Recruiting
This is a Phase 3 trial to evaluate the BP-lowering effect of lorundrostat (an aldosterone synthase inhibitor) in subjects with uncontrolled and resistant hypertension taking between 2 and 5 anti-hypertensive (AHT) medications.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/12/2024
Locations: Synexus (Radiant Research, Inc) - Chicago, Chicago, Illinois +3 locations
Conditions: Hypertension
A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects With Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen
Recruiting
a Phase 2 trial to evaluate the blood pressure-lowering effect of lorundrostat (an aldosterone synthase inhibitor), administered on a background of a standardized anti-hypertensive (AHT) medication regimen, in subjects with uncontrolled and/or treatment-resistant hypertension.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/11/2024
Locations: Eagle Clinical Research, Chicago, Illinois +3 locations
Conditions: Hypertension
Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)
Recruiting
The primary objective of the study is to determine the effect of seralutinib on improving exercise capacity in subjects with WHO Group 1 PAH who are FC II or III. The secondary objective for this trial is to determine time to clinical worsening.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
06/10/2024
Locations: Northwestern Memorial Hospital, Clinical Research Unit, Chicago, Illinois +1 locations
Conditions: Pulmonary Arterial Hypertension
SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN
Recruiting
The purpose of this single-arm interventional study is to evaluate the long-term safety, efficacy, and durability of the Symplicity Spyral system in subjects treated with renal denervation. Additionally, long-term follow-up data will also be collected from eligible subjects previously treated in the SPYRAL PIVOTAL-SPYRAL HTN-OFF MED and SPYRAL HTN-ON MED studies.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/07/2024
Locations: University of Chicago Medicine, Chicago, Illinois +2 locations
Conditions: Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases, Diabetes Mellitus